Drug Trial Radar · NCT06205121
Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis
Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
96
Planned (sponsor's estimate)
Start
Mar 21, 2024
Primary completion
Aug 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Molecure S.A.Industry
- Sponsor type
- Industry
- First posted
- Jan 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, randomized, double-blind, placebo-controlled, adaptive, multicenter study to evaluate the efficacy, safety, tolerability, Pharmacodynamics (PD), and Pharmacokinetics (PK) of OATD-01 in the treatment of subjects with active pulmonary sarcoidosis.
Conditions
- Pulmonary Sarcoidosis
Interventions
OATD-01Drug
OATD-01 is an oral inhibitor of chitinase-1 (CHIT1)
PlaceboDrug
Matching placebo tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Response to treatmentTime frame: After 12 weeks of treatment, i.e. from baseline (randomization) visit to End-of-Treatment (EOT) visit.
Locations
28 sites in 8 countries. Site status is shown where the registry gives one.
Molecure Investigative Site
Birmingham, Alabama · Withdrawn
Molecure Investigative Site
Kansas City, Kansas · Withdrawn
Molecure Investigative Site
Baltimore, Maryland · Recruiting
Molecure Investigative Site
Rochester, Minnesota · Withdrawn
Molecure Investigative Site
Cleveland, Ohio · Recruiting
Molecure Investigative Site
Philadelphia, Pennsylvania · Recruiting
Molecure Investigative Site
Charleston, South Carolina · Recruiting
Molecure Investigative Site
Vejle, Denmark · Withdrawn
Molecure Investigative Site
Bobigny, France · Withdrawn
Molecure Investigative Site
Montpellier, France · Recruiting
Molecure Investigative Site
Paris, France · Recruiting
Molecure Investigative Site
Paris, France · Recruiting
Molecure Investigative Site
Essen, Germany · Recruiting
Molecure Investigative Site
Freiburg im Breisgau, Germany · Recruiting
Molecure Investigative Site
Mainz-GE, Germany · Recruiting
Molecure Investigative Site
Corfu, Greece · Withdrawn
Molecure Investigative Site
Heraklion, Greece · Recruiting
Molecure Investigative Site
Pátrai, Greece · Recruiting
Molecure Investigative Site
Thessaloniki, Greece · Recruiting
Molecure Investigative Site
Nieuwegein, Netherlands · Recruiting
Molecure Investigative Site
Rotterdam, Netherlands · Recruiting
Molecure Investigative Site
Bergen, Norway · Recruiting
Molecure Investigative Site
Oslo, Norway · Recruiting
Molecure Investigative Site
Birmingham, United Kingdom · Recruiting
Molecure Investigative Site
Cambridge, United Kingdom · Withdrawn
Molecure Investigative Site
Edinburgh, United Kingdom · Recruiting
Molecure Investigative Site
London, United Kingdom · Recruiting
Molecure Investigative Site
London, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.